Sources Used in Current Review
2018 review performed by Mutasim Elfahal, PhD, DABCC.
Lindeman NI, et al. EGFRおよびALKチロシンキナーゼ阻害剤に対する肺がん患者の選択のための分子検査ガイドライン：College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathologyからのガイドライン。 J Mol Diagn. 2013 Jul;15(4):415-53.
Lindeman NI, et al.Updated Molecular Testing Guideline for the Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors（標的チロシンキナーゼ阻害剤による治療のための肺がん患者の選択に関する分子検査ガイドライン）。 Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018 Mar;20(2):129-159.
Lusky, Karen. Molecular tumor board: a patient with ALK-rearranged lung cancer. Cap Today 2018年2月.
Chia PL, Mitchell P, Dobrovic A, John T. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol. 2014 Nov 20;6:423-32.
Sources Used in Previous Reviews
Markman, M. (Updated 2013 July 15). Genetics of Non-Small Cell Lung Cancer（非小細胞肺がんの遺伝学）。 Medscape Reference . Available online at http://emedicine.medscape.com/article/1689988-overview. Accessed July 2013.
Lindeman, N.et. al. (2013 June). Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors, Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med v 137, . Available online at http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2012-0720-OA. Accessed July 2013.
Wallander, M.et. al. (2013年7月更新) 肺がん. ARUP Consult . Available online at http://www.arupconsult.com/Topics/LungCancer.html?client_ID=LTD. Accessed July 2013.
(Revised 2012 March 21). クリゾチニブ. American Cancer Society . Available online at http://www.cancer.org/treatment/treatmentsandsideeffects/guidetocancerdrugs/crizotinib. Accessed July 2013.
Chustecka, Z. (2012 September 30). Crizotinib Now Standard of Care for ALK+ NSCLC（クリゾチニブがALK+ NSCLCの標準治療に）。 Medscape Medical News from the 2012 European Society for Medical Oncology (ESMO) Congress .
http://www.medscape.com/viewarticle/771853でオンライン公開されています。 Accessed July 2013.
Markman, M. (2012 April 4). 遺伝は非喫煙者のNSCLCの転帰にどのように影響するか？ Medscape Today News from Cancer v 118: 729-739. . Available online at http://www.medscape.com/viewarticle/761054. Accessed July 2013.
(2013 June 17). クリゾチニブは一部の進行性肺がん患者の無増悪生存期間を改善する。 米国国立がん研究所. Available online at http://www.cancer.gov/clinicaltrials/results/summary/2013/crizotinib-NSCLC0613. Accessed July 2013.
(Reviewed 2011 March). ALK. Genetics Home Reference . Available online at http://ghr.nlm.nih.gov/gene/ALK. Accessed July 2013.
Mulcahy, N. (2012 March 22). NCCNのNSCLCガイドラインは変化に富んでいる。 Medscape Medical News . Available online at http://www.medscape.com/viewarticle/760722. Accessed July 2013.
(Upated 2010 June) Getting the Facts, Anaplastic Large Cell Lymphoma. リンパ腫研究財団 . Available online at http://www.lymphoma.org/atf/cf/%-51b5-427b-be48-e6af871acec9%7D/ANAPLASTIC10.PDF. Accessed July 2013.
(2012 May 16). NIHが支援する臨床試験で使用された薬剤が、前治療歴のある癌の子供に効果を示した。 米国国立がん研究所. Available online at http://www.cancer.gov/newscenter/newsfromnci/2012/crizotinib. Accessed July 2013.
Nelson, R. (2011 August 26). FDA Approves New Drug for Advanced NSCLC. Medscape Medical News . Available online at . Accessed July 2013.
Nelson, R. (2012 October 25). Crizotinib、欧州で条件付き販売承認を取得。 Medscape Medical News . Available online at http://www.medscape.com/viewarticle/773280. Accessed July 2013.
(Revised 2012 October 18). Tumor Markers. American Cancer Society . http://www.cancer.orgからオンラインで入手可能。 Accessed July 2013.
Yi E., et al. Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH. Journal of Thoracic Oncology March 2011 – Volume 6 – Issue 3 – Pp 459-465. Available online at http://journals.lww.com/jto/Fulltext/2011/03000/Correlation_of_IHC_and_FISH_for_ALK_Gene.8.aspx#.
Gregory J. Tsongalis, PhD, HCLD, CC, Professor of Pathology, Director, Molecular Pathology, Dartmouth Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, Lebanon, NH.
。